Brazilian Outlook

Novo Nordisk Looks Beyond Weight Loss to Longevity and Aesthetics




Novo’s blockbuster drugs could pull it into buzzier areas of healthcare, chief executive Mike Doustdar said, as the Ozempic maker seeks to lessen its reliance on obesity and diabetes.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *